Skip to content

Pandemic Preparedness

Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.

ThumbnailKalusPhotoPlasma & Platelets

How can we guarantee the supply of blood products to patients? Especially with short-life platelet concentrates, even in times of epidemics?

Priv-Doz. Dr. med. Ulrich Kalus
Charité
Berlin, Germany 

EN DE

ThumbnailHindawiPhoto

Platelets & Plasma

Blood safety during the SARS-CoV-2 pandemic and beyond: the impact of pathogen inactivation with the INTERCEPT Blood System

Prof. Salwa Ibrahim Hindawi
King Abdulaziz University
Jeddah, Saudi Arabia

EN DE ES IT 

ThumbnailBareaPhotoPlatelets & Plasma

COVID-19: Lessons learned to safeguard the continuity of blood supply in the Madrid region

Dr. Luisa Maria Barea Garcia, MD
Centro de Transfusión de la Comunidad de Madrid
Madrid, Spain

EN DE ES IT  

ThumbnailStramerPlatelets & Plasma

Vector-borne diseases in the Americas and Europe - NAT vs PI

Dr. Susan Stramer, PhD
American Red Cross
Gaithersburg, Maryland, USA

EN

ThumbnailHervig

Plasma & Platelets

Evolution of the level of blood safety and impact on patient safety: a historic perspective

Dr. Tor Hervig
Haugesund Hospital / University of Bergen
Bergen, Norway

EN   

  

cerus_large_2x

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0